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Two hallmarks of glioblastoma multiforme, the most common malignant brain cancer in humans, are aggres-
sive growth and the ability of single glioma cells to disperse throughout the brain. These characteristics render 
tumors resistant to current therapies and account for the poor prognosis of patients. Although it is known that 
oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth 
and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. Here, we 
report that PDGFR_ signaling in glioblastomas leads to Src-dependent phosphorylation of the guanine nucle-
otide exchange factor Dock180 at tyrosine 1811 (Dock180Y1811) that results in activation of the GTPase Rac1 and 
subsequent cell growth and invasion. In human glioma cells, knockdown of Dock180 and reversion with an 
RNAi-resistant Dock180Y1811F abrogated, whereas an RNAi-resistant Dock180WT rescued, PDGFR_-promoted 
glioma growth, survival, and invasion. Phosphorylation of Dock180Y1811 enhanced its association with CrkII 
and p130Cas, causing activation of Rac1 and consequent cell motility. Dock180 also associated with PDGFR_ to 
promote cell migration. Finally, phosphorylated Dock180Y1811 was detected in clinical samples of gliomas and 
various types of human cancers, and coexpression of phosphorylated Dock180Y1811, phosphorylated SrcY418, 
and PDGFR_ was predictive of extremely poor prognosis of patients with gliomas. Taken together, our find-
ings provide insight into PDGFR_-stimulated gliomagenesis and suggest that phosphorylated Dock180Y1811 
contributes to activation of Rac1 in human cancers with PDGFRA amplification.
*OUSPEVDUJPO
Glioblastoma multiforme (GBM), the most common malig-
nant brain cancer in humans, is characterized by high prolif-
eration rates, extensive single-cell infiltration into the adjacent 
and distant brain parenchyma, and robust neoangiogenesis, 
which together inevitably confer resistance to current treat-
ment modalities (1–3). Recently, coordinated genomic analyses 
of large cohorts of clinical GBM specimens rank PDGFR_ third 
among the top 11 amplified genes in GBMs (4, 5). Further inte-
grated analysis revealed that PDGFR_ is preferentially amplified 
within a clinically relevant subtype of glioblastomas (6). Overex-
pression of PDGFR_ and its ligand, PDGF-A, in clinical gliomas 
is associated with a poor prognosis and shorter survival time for 
patients (1–3). PDGFR_ signaling promotes cell proliferation, 
survival, and motility through the PI3K, Src, and PLCa pathways 
(7). Recently, we reported that activation of PDGFR_ signaling 
drives gliomagenesis of Ink4a/Arf-deficient mouse astrocytes 
and human glioma cells in the brain (8).
Rac1 is a small Rho GTPase and a molecular switch essential for 
controlling cell movement, survival, and other cellular functions 
(9). Rac1 is activated by guanine nucleotide exchange factors (GEFs) 
that promote the exchange of GDP to GTP. There are 2 distinct 
families of Rho GEFs, those that contain a Dbl-homology (DH) 
domain and those that are devoid of it. The dedicator of cytokine-
sis (Dock) family of GEFs, with 11 members in humans, lacks DH 
domains, but instead has Dock-homology region–1 (DHR-1) and 
DHR-2 domains (10). Dock1 orthologs in C. elegans, Drosophila, and 
mammals (in which it is known as Dock180) modulate cell migra-
tion, myoblast fusion, dorsal closure, and cytoskeletal organization 
through activation of Rac1 (11). Dock180 facilitates GDP/GTP 
exchange of Rac1 through its DHR-2 domain, but requires forma-
tion of a complex with engulfment and cell motility 1 (ELMO1). 
This bipartite GEF complex synergistically functions upstream of 
Rac1 and promotes Rac1-dependent cell migration and phagocyto-
sis (11). In cancers, Rac1 mediates tumor cell growth, survival, and 
invasion in response to various stimuli (9). Although neither Rac1 
nor its GEFs, such as Dock180, are known to be overexpressed or 
mutated in human cancers (10), aberrant and constitutive activa-
tion of Rac1 might be involved in tumorigenesis and invasion.
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Rac1 GEF couples receptor tyrosine kinases (RTKs) to Rac1 
(12). PVR, a homolog of PDGF/VEGF receptor in Drosophila, is 
essential for cell migration and spatial guidance of embryonic 
blood cell precursors (13). Significantly, the Dock180/ELMO1 
complex mediates PVR-induced cell migration of these precur-
sor cells through Rac1 during Drosophila development (14). Previ-
ously, some of us reported that Dock180 plays a critical role in 
promoting glioma cell invasion through activation of Rac1 (15). 
Here, in order to determine whether Dock180 activation of Rac1 
mediates PDGFR_ signaling in glioblastomas, we examined the 
role of regulatory tyrosine phosphorylation (p-Y) of Dock180 in 
PDGFR_-promoted glioma tumorigenesis. Our results showed 
that Dock180 was specifically phosphorylated at tyrosine residue 
1811 (p-Dock180Y1811) by PDGFR_-activated Src kinase in glio-
mas, resulting in stimulation of Dock180 interaction with CrkII 
and p130Cas as well as subsequent Rac1 activation that culminated 
in PDGFR_-promoted glioma growth, survival, and invasion. 
These findings suggest what we believe to be a previously uniden-
tified intervention approach in the treatment of gliomas: targeting 
the PDGFR/Src/Dock180/Rac1 signaling cascade.
3FTVMUT
Dock180 mediates PDGFR_-stimulated glioma cell migration and survival 
in vitro and tumor growth, survival, and invasion in the brain. To estab-
lish the role of Dock180 in PDGFR_-stimulated glioma growth, 
survival, and invasion, we first examined the expression of endog-
enous PDGFR_ in various human glioma cell lines. The LNZ308, 
LN319, LN443, LN444, and SNB19 glioma cell lines endogenously 
expressed PDGFR_ at moderate to high levels, whereas U87, U251, 
U373, T98G, LN18, and LN235 glioma cells had lower-level expres-
sion of PDGFR_ (Figure 1A). To correlate expression levels of 
PDGFR_ proteins with PDGFRA gene status in these glioma cells, 
we performed quantitative PCR analyses (16). Consistent with the 
levels of PDGFR_ protein, increased copy numbers of the PDGFRA 
gene were found in LNZ308, LN319, LN443, LN444, and SNB19 
glioma cells. Additionally, in agreement with a previous report (17), 
PDGFRA gene amplification was observed in primary human glioma 
GBM5 cells, but not in GBM6 cells, GBM14 cells, or other cell lines 
examined (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI58559DS1). Heterogeneous 
levels of PDGFR_ expression in various glioma cell lines reflect pref-
erential amplification of PDGFRA in the clinically relevant proneu-
ral subtype of glioblastomas, but not in other subclasses (6). More-
over, LN443 and LN444 cells also expressed a group of genes that 
were statistically similar to a subgroup of signature genes in the pro-
neural subtype of clinical GBMs, such as SOX3, GABRA3, GALNT13, 
MAPT, and NRXN2 (Supplemental Table 1 and ref. 6).
To determine whether Dock180 mediates PDGFR_-stimu-
lated glioma cell growth and migration, we assessed the effect 
of Dock180 inhibition on PDGFR_ stimulation. Knockdown of 
endogenous Dock180 by a pool of siRNAs markedly impaired basal 
and PDGF-A–stimulated Rac1 activities and in vitro cell migration 
of LN443 and LN444 cells (Figure 1, B and C). These data suggest 
that Dock180 is critical for PDGF-A/PDGFR_–induced Rac1 acti-
vation and glioma cell migration.
To determine the function of Dock180 in PDGFR_-stimulated 
tumorigenesis in vivo, we stably knocked down Dock180 in LN444/
PDGF-A gliomas using 2 shRNAs (shRNA1 and shRNA2). Over-
expression of PDGF-A by LN444 cells that express endogenous 
PDGFR_ (referred to herein as LN444/PDGF-A cells) promoted 
the expression of a subgroup of the proneural signature genes (Sup-
plemental Table 1) and gliomagenesis in the brain (8). Knockdown 
of Dock180 in LN444/PDGF-A cells did not affect expression of 
exogenous PDGF-A, endogenous PDGFR_, Akt, and Erk1/2 pro-
teins, but reduced the PDGFR_-stimulated phosphorylation of Akt 
and Erk1/2 compared with the control (Figure 2A). Knockdown of 
Dock180 by 2 separate shRNAs in LN444/PDGF-A cells had a min-
imal effect on the population doubling times of cells cultured in 
media containing 10% FBS, compared with that of LN444/GFP or 
control shRNA (shControl) cells (Figure 2B). However, knockdown 
of Dock180 markedly decreased PDGF-A/PDGFR_–stimulated cell 
survival (Figure 2C; apoptotic index at 48 hours with starvation) 
and migration (data not shown). These data suggest that depletion 
of Dock180 inhibits PDGFR_-stimulated Rac1/MAPK and Rac1/
Akt signaling as well as glioma cell survival and migration in vitro.
Next, we separately implanted LN444/PDGF-A/shControl, 
LN444/PDGF-A/Dock180-shRNA1 (referred to herein as 
shDock180-1), and LN444/PDGF-A/Dock180-shRNA2 
(shDock180-2) cells into the brains of mice. Compared with con-
trol LN444/GFP gliomas, overexpression of PDGF-A by LN444 
gliomas significantly enhanced tumor growth, survival, and inva-
sion (8), whereas knockdown of Dock180 markedly suppressed 
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2, D–S, and Supplemental Figure 2). When various brain sections 
from the different tumors were examined by immunohistochemical 
(IHC) staining, ectopically expressed PDGF-A enhanced cell pro-
liferation compared with the control (Figure 2, H, I, and R, and 
Supplemental Figure 2, I and J). However, depletion of Dock180 
significantly decreased LN444 tumor cell proliferation compared 
with shControl tumors (Figure 2, I–K and R, and Supplemental 
Figure 2, J–L). To a similar extent, compared with LN444/GFP, 
overexpression of PDGF-A resulted in a marked decrease in cell 
apoptosis (Figure 2, L, M, and S, and Supplemental Figure 2, N 
and M). Knockdown of Dock180 in LN444/PDGF-A tumors also 
significantly increased cell apoptosis compared with shControl 
tumors (Figure 2, M–O and S, and Supplemental Figure 2, N–P). 
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PDGFR_ by PDGF-A enhances glioma growth, survival, and inva-
sion and that Dock180 is required for PDGFR_-promoted glioma-
genesis in the brain.
Dock180 is specifically phosphorylated at Y1811 by PDGFR_ stimulation 
in glioma cells. Since Dock180 activates Rac1 (11) and mediates PVR-
induced cell migration in vivo (14), we hypothesized that PDGFR_ 
signaling promotes glioma cell growth, survival, and invasion 
through p-Y of Dock180, leading to activation of Rac1. To test this 
hypothesis, we first examined whether PDGF-A stimulation induces 
p-Y of endogenous Dock180 in glioma cells. PDGF-A stimulation of 
LN443 or LN444 glioma cells induced distinct p-Y of PDGFR_, p-Y 
of Dock180, and activation of Rac1, whereas inhibition of PDGF-A 
stimulation by a PDGFR inhibitor, AG1296 (which selectively inhib-
its RTK activities of PDGFR_ and PDGFR` and PDGF-mediated sig-
naling in cells; ref. 18), impaired PDGF-A–induced p-Y of PDGFR_, 
p-Y of Dock180, and Rac1 activation in glioma cells (Figure 3A).
Next, we computationally examined potential p-Y sites of the 
Dock180 protein (using the SCANSITE tool, http://scansite.mit.
edu; and the NetPhosK 1.0 server, http://www.cbs.dtu.dk/services/ 
NetPhosK) and identified 27 hypothetical p-Y sites, including 
Y1811, a residue in Dock180 predicted to be a target of Src and 
other kinases. To determine whether PDGFR_ stimulates glioma 
growth, survival, and invasion and Rac1 activation through one 
or more specific p-Y sites of Dock180, we constructed various 
Dock180 deletion mutants (Figure 3B) and cotransfected these 
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PDGFR_68,9 mutant (19), into human HEK293T cells. Coexpres-
sion of PDGFR_68,9 with Dock180WT induced p-Y of Dock180. Dele-
tions of the DHR-1 (6DHR1) or DHR-2 (6DHR2) domain from the 
Dock180 peptide that interacts with PIP3 or Rac1, respectively (11), 
had no effect on PDGFR_68,9-induced p-Y of Dock180 (Figure 3, C 
and D). However, removal of a C-terminal segment, including the 
DHR2 domain (WT-ApaI), markedly reduced PDGFR_68,9-induced 
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(∆DHR1-ApaI) further diminished the induced p-Y of Dock180, 
suggestive of a major p-Y site located at the C terminus. Examina-
tion of potential p-Y sites within the targeted domain of Dock180 
identified a single p-Y candidate site at Y1811 (Figure 3B). To ascer-
tain that Y1811 is a major p-Y site of Dock180 induced by PDGFR_, 
Y1811 was mutated to phenylalanine (F) in the full-length Dock180 
protein. PDGFR_68,9-induced p-Y was markedly reduced for Dock-
180Y1811F compared with the stimulated p-Y of Dock180WT (Figure 
3E). Incomplete abrogation of PDGF-A–induced p-Y of Dock180 
corroborates with the results in Figure 3D, which indicates that 
there is a minor p-Y site in the DHR-1 domain of Dock180 protein. 
When we examined aa sequences surrounding Y1811 in Dock180 
of various species and Dock family members, we found that Y1811 
and most of its surrounding aa residues were highly conserved in 
Dock180 among these species (Figure 3F), but not other members 
of the Dock family (Supplemental Figure 3). Taken together, these 
results suggest Y1811 of Dock180 as a major p-Y site that is specifi-
cally phosphorylated by PDGFR_ in glioma cells.
p-Dock180Y1811 is required for PDGFR_-stimulated glioma cell migration 
and survival in vitro and tumor growth, survival, and invasion in the brain. We 
generated a rabbit polyclonal antibody that specifically recognizes the 
p-Dock180Y1811 protein. This anti–p-Dock180Y1811 antibody detected 
a strong signal of p-Y of endogenous Dock180 in U87, U373, SNB19, 
and LN444 glioma cells stimulated with PDGF-A, but weak or absent 
signal in these glioma cells treated with EGF or HGF, compared with 
the control (Figure 4A), indicative of its selectivity for PDGFR_-
induced p-Dock180Y1811. Next, we stably reexpressed an shRNA-
resistant Dock180WT* or Dock180Y1811F* in poorly tumorigenic 
LN444/PDGF-A/shDock180-2 cells in which endogenous Dock180 
had been stably depleted (Figure 2A). The exogenous Dock180WT* or 
Dock180Y1811F* proteins were expressed at levels comparable to those 
of endogenous Dock180 in shControl-expressing cells (Figure 4B). 
The anti–p-Dock180Y1811 antibody detected p-Y of Dock180WT*, but 
not Dock180Y1811F*, proteins in these cells. Moreover, Dock180WT*, 
but not Dock180Y1811F*, rescued the PDGF-A–induced phosphory-
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rescued the PDGF-A–induced phosphorylation of Akt (Figure 4B), 
which suggests that p-Dock180Y1811 is important for Rac1/MAPK 
signaling. Although no appreciable effect was seen on cell population 
doubling (Supplemental Figure 4A), reexpression of Dock180WT*, but 
not Dock180Y1811F*, in LN444/PDGF-A/shDock180-2 cells restored 
PDGF-A–stimulated cell viability and migration in vitro (Supple-
mental Figure 4, B and C). Importantly, when various engineered 
LN444 cells were implanted into the brains of mice, restoration of 
Dock180WT*, but not Dock180Y1811F*, in poorly tumorigenic LN444/
PDGF-A/shDock180-2 cells rescued PDGFR_-promoted tumor 
growth, survival, and invasion (Figure 4, C–E, L, and M, and Supple-
mental Figure 5, A–F). Additionally, reexpression of Dock180WT*, 
but not Dock180Y1811F*, in LN444/PDGF-A/shDock180-2 gliomas 
also rescued PDGFR_-induced cell proliferation and inhibited cell 
apoptosis (Figure 4, F–K, N, and O, and Supplemental Figure 5, G–L). 
In addition, compared with the control or Dock180Y1811F*, reexpres-
sion of Dock180WT* by LN444/PDGF-A/shDock180-2 gliomas also 
significantly increased tumor angiogenesis and microglia growth, 
but had a minimal effect on the tumor infiltration of macrophages 
(Supplemental Figure 6). Taken together, these data suggest that p-Y 
of Dock180Y1811 is necessary for PDGFR_-stimulated glioma growth, 
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p-Dock180Y1811 mediates PDGFR_-stimulated recruitment of CrkII 
and p130Cas and Rac1 activation. Y1811 is located at the C-termi-
nal domain of Dock180, which interacts with CrkII and medi-
ates Dock180/CrkII/p130Cas/Rac1 signaling in promoting cell 
motility (Figure 3B and ref. 11). Thus, we sought to determine 
whether p-Dock180Y1811 is critical for PDGFR_-induced forma-
tion of a Dock180/CrkII/p130Cas complex and activation of Rac1 
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either Flag-tagged Dock180WT or Flag-tagged Dock180Y1811F in 
HEK293T cells. PDGF-A stimulation induced p-Y of WT PDGFR_ 
and Dock180WT and association of Dock180WT with CrkII and 
p130Cas (Figure 5A). In contrast, co-IP experiments showed that 
the Dock180Y1811F mutation substantially attenuated PDGFR_-
induced p-Y of Dock180 and interaction of Dock180 with CrkII 
and p130Cas, whereas no effect on p-Y of PDGFR_ was observed. 
Treatment of LN443 or LN444 cells with exogenous PDGF-A or 
ectopic PDGF-A expression induced the association of Dock180 
with CrkII and p130Cas and activated Rac1 (Figure 5B). However, 
restoration of Dock180Y1811F*, but not Dock180WT*, in LN444/
PDGF-A/shDock180 cells in which endogenous Dock180 had 
been depleted impeded PDGF-A induction of p-Dock180Y1811, 
association of Dock180 with CrkII, and activation of Rac1 
(Figure 5C). These results indicate that p-Dock180Y1811 medi-
ates PDGFR_-induced association of Dock180 with CrkII and 
p130Cas and activation of Rac1 in glioma cells.
Src mediates PDGFR_ stimulation of p-Dock180Y1811 and glioma cell 
migration. In addition to the potential p-Y sites of Dock180, our 
computational analysis also suggested Dock180Y1811 as a puta-
tive substrate site for Src. Src is a non-RTK that plays a crucial 
role in tumor progression and tumorigenesis promoted by aber-
rant activation of RTK signaling, including PDGFR (20). Thus, 
we hypothesized that PDGFR_ promotes glioma tumorigenesis 
and invasion through Src stimulation of p-Dock180Y1811 and 
activation of Rac1. To test this hypothesis, LN444 cells were pre-
treated with or without the Src inhibitor PP2, its PP3 inactive 
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prior to stimulation with PDGF-A. Treatment of LN444 cells 
with PP2 or SU6656, but not vehicle control or PP3, marked-
ly decreased PDGF-A–induced p-Y of Dock180, p-SrcY418, and 
Rac1 activity (Figure 6A). Of note, the PDGF-A–induced p-Y of 
PDGFR_ remained unchanged in the presence or absence of 
the Src inhibitors. When various treated LN444 cells were ana-
lyzed for in vitro migration, inhibition of Src by PP2 or SU6656, 
but not the control or PP3, significantly abrogated PDGF-A–
induced cell migration (Figure 6B). The incomplete inhibition of 
PDGF-A–induced p-Y of Dock180 by Src inhibitors could be due 
to a minor p-Y site in Dock180 (Figure 3), which suggests that 
other kinases, such as PI3K, may contribute to p-Y of Dock180. 
To test this possibility, we treated LN444 cells with the PI3K 
inhibitor LY294002 prior to PDGF-A stimulation. We found 
that inhibition of PI3K did not affect PDGF-A–induced p-Y of 
Dock180, but markedly decreased PDGF-A–induced Rac1 activ-
ity and cell migration, compared with controls (Supplemental 
Figure 7 and ref. 21), which suggests that a different kinase 
mediates PDGF-A–induced p-Y at this minor site.
To determine whether Src phosphorylates Dock180Y1811, we sep-
arately cotransfected cDNAs of Flag-tagged Dock180WT or Flag-
tagged Dock180Y1811F together with Src WT, a kinase-dead (KD) 
mutant, or a CA mutant (Y527F) into HEK293T cells. Without 
stimulation, CA Src, but not WT or KD Src, induced p-Y of Flag-
tagged Dock180WT (Figure 6C). In contrast, coexpression of Flag-
tagged Dock180Y1811F with CA Src severely reduced its p-Y, whereas 
no p-Dock180Y1811F was detected when WT or KD Src were coex-
pressed in HEK293T cells. To validate that Src mediates PDGFR_ 
stimulation of p-Dock180Y1811, Flag-tagged Dock180WT and Flag-
tagged Dock180Y1811F were separately cotransfected with WT 
PDGFR_ and KD Src mutant into HEK293T cells. After 48 hours, 
cells were serum starved and stimulated with PDGF-A. Treatment 
with PDGF-A induced p-Y of PDGFR_ and Dock180, whereas 
coexpression of KD Src markedly inhibited PDGF-A–induced p-Y 
of Dock180, with no effect on PDGF-A–induced p-Y of PDGFR_ 
(Figure 6D). Furthermore, Dock180pY1811F significantly prevent-
ed PDGF-A–stimulated p-Y of Dock180, but not p-Y of PDGFR_. 
Coexpression of KD Src with Dock180Y1811F further diminished 
'JHVSF
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PDGF-A–stimulated p-Y of Dock180 (Figure 6D). Again, simi-
lar to our data in Figure 3, the residual PDGF-A–induced p-Y of 
Dock180 (Figure 6, C and D) was attributable to the existence of a 
minor p-Y site in Dock180 that is a substrate for another kinase.
Next, we performed an in vitro p-Y assay by incubating purified 
recombinant (His)6-Dock180WT or (His)6-Dock180Y1811F proteins 
with a recombinant active Src. Dock180WT, but not Dock180Y1811F, 
was phosphorylated by Src (Figure 6E). Next, we performed a 
reconstitution assay for nucleotide-free Rac binding (22, 23). In 
the absence of the recombinant Src, when immunoprecipitated 
Dock180WT or Dock180Y1811F was dephosphorylated by a protein 
tyrosine phosphatase (PTP), minimal Dock180-Rac1 interaction 
was seen. However, when a recombinant Src was added, substan-
tial p-Dock180WT, but not p-Dock180Y1811F, was induced, accom-
panied with an increase in association of Dock180 with Rac1 
(Figure 6F). Finally, we knocked down endogenous Src using 2 
separate shRNAs (shRNA4 and shRNA5) in LN444/PDGF-A/
shDock180 cells with or without reexpression of Dock180WT* or 
Dock180Y1811F* (Figure 6G). p-Dock180Y1811 and Rac1 activation 
were observed in LN444/PDGF-A/shControl or Dock180WT*-
reexpressing cells. However, effective depletion of Src markedly 
decreased PDGF-A–induced p-Y of Dock180WT* and Rac1 activity 
in LN444/PDGF-A/shControl and Dock180WT*-restored cells, but 
had no effect in vector or Dock180Y1811F* cells. As a result, knock-
down of Src also inhibited PDGF-A stimulation of cell migration 
in the control and Dock180WT*-restored cells (Figure 6H). Taken 
together, these data indicate that Src mediates PDGFR_ stimula-
tion of glioma cell migration through specific p-Y of Dock180Y1811 
and activation of Rac1.
PDGF-A–induced association of Dock180 with PDGFR_ is necessary for 
cell migration. We sought to determine whether endogenous Dock180 
also associates with PDGFR_ in glioma cells by separately treating 
SNB19, LN444, and LN443 cells with PDGF-A. Treatment with 
PDGF-A induced an association of Dock180 with PDGFR_ in all 3 
cell lines (Figure 7A). To identify which region or domain in Dock180 
mediates its association with PDGFR_, we generated several dele-
tion mutants lacking various functional binding domains (Figure 
3B and Figure 7B). When these Dock180 deletion mutants were 
separately cotransfected with PDGFR_68,9 into HEK293T cells, all 
Dock180 deletion mutants — as well as a short fragment of Dock180, 
1–159 mutant — were able to interact with CA PDGFR_68,9 (Figure 
7, C and D). This suggests that the N-terminal region of aa residues 
1–159 of Dock180 protein is involved in its association with acti-
vated PDGFR_. To confirm this, we coexpressed PDGFR_68,9 with 
a Flag-tagged Dock180 deletion mutant that lacks its N-terminal 
1–159 aa residues (Dock1806160) in HEK293T cells and found that 
the induced Dock180 association with PDGFR_68,9 was abrogated 
in cells (Figure 7E), whereas the Dock180Y1811F mutant did not affect 
Dock180 association with PDGFR_68,9 (Supplemental Figure 8). To 
further examine whether this association affects PDGF-A stimula-
tion of p-Y of Dock180 and glioma cell migration, we used LN444/
PDGF-A/shDock180-2 cells, in which PDGFR_ was activated by 
PDGF-A expression and endogenous Dock180 was stably depleted 
(Figure 2A). When a shRNA-resistant Dock180WT* or a shRNA-resis-
tant Dock1806160* mutant were separately reexpressed, Dock180WT* 
restored PDGF-A–induced association of Dock180 and ELMO1 with 
WT PDGFR_ and activation of Rac1, whereas Dock1806160* mark-
edly inhibited its association with PDGFR_ and ELMO1 as well as 
Rac1 activation (Figure 7F). Furthermore, restoration of Dock180WT* 
enhanced PDGF-A–stimulated LN444/PDGF-A/shDock180-2 cell 
migration, whereas reexpression of the Dock1806160* mutant was 
unable to render the cells responsive to PDGF-A stimulation of cell 
migration (Figure 7G). Finally, reexpression of a shRNA-resistant 
Dock1806160-Y1811F* mutant (which lacks both the N-terminal 1–159 
aa residues and the Y1811 phosphorylation site) attenuated PDGF-A 
stimulation of Rac1 activities and had an additive effect on reducing 
cell migration compared with that caused by individual mutations 
(Figure 7H). Together, these results demonstrated that the N-termi-
nal region of Dock180 (aa residues 1–159) formed a complex with 
PDGFR_ and ELMO1 and modulated PDGF-A–stimulated glioma 
cell migration without affecting the induced p-Y of Dock180.
Src-dependent p-Dock180Y1811 is important for PDGF-A–induced 
Dock180 association with p130Cas and CrkII; activation of Akt, Erk1/2, and 
Rac1; and cell migration of primary GBM cells with PDGFR_ amplifica-
tion. To determine whether Src-dependent p-Y of Dock180Y1811 is 
required for Rac1 activation and cell migration in primary GBM cells 
with PDGFR_ overexpression, we used primary GBM5 (PDGFRA 
gene amplification), GBM6 (EGFR gene amplification and EGFR-
vIII overexpression), and GBM14 (no PDGFRA or EGFR gene ampli-
fication) cells (Supplemental Figure 1 and refs. 17, 24). PDGF-A 
stimulation of primary GBM5 cells with PDGFR_ overexpression 
increased p-Y of Dock180Y1811 and Rac1 activities compared with 
GBM6 and GBM14 cells (Figure 8A). Consistent with our results 
in Figure 4A, GBM6 cells with EGFRvIII overexpression minimally 
increased p-Y of Dock180Y1811 and increased Rac1 activities with 
or without PDGF-A stimulation. PDGFR_ stimulation also pro-
moted the association among Dock180, p130Cas, CrkII, p-Akt, 
p-Erk1/2, and Rac1 activities in GBM5 cells, whereas AG1296, PP2, 
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the association of Dock180, p130Cas, CrkII, p-Akt, p-Erk1/2, Rac1 
activities, and cell migration of GBM5 cells (Figure 8, B and D). 
To further define this signaling, we transiently transfected GBM5 
cells with a Dock180 siRNA pool or control siRNA. Knockdown of 
Dock180 also inhibited PDGF-A stimulation of these biochemical 
and cellular behaviors in GBM5 cells (Figure 8, C and D). Therefore, 
these results recapitulated our in vitro and in vivo observations in 
LN443 and LN444 cells, which further suggests that Src-dependent 
p-Dock180Y1811 is critical for PDGFR_-stimulated Dock180 asso-
ciation with p130Cas, CrkII, p-Akt, p-Erk1/2, Rac1 activities, and cell 
migration in glioma cells.
p-Dock180Y1811 is present with PDGFR_ and p-SrcY418 in human clini-
cal glioma specimens. Based on accumulating evidence supporting 
an important function of p-Dock180Y1811 in PDGFR_-stimulated 
glioma tumorigenesis, we sought clinical evidence for a link among 
p-Dock180Y1811, PDGFR_, and active Src. We immunostained a 
total of 134 clinical glioma tumor samples using an anti-PDGFR_ 
antibody. PDGFR_ proteins were detected in 3 of 26 WHO grade II 
gliomas (11.5%), 6 of 30 WHO grade III gliomas (20%), and 24 of 78 
GBM specimens (30.8%), similar to previously reported frequencies 
(4, 6). Subsequently, we performed IHC analyses of these PDGFR_-
expressing GBM specimens using anti–p-SrcY418 and our specific 
anti–p-Dock180Y1811 antibodies. PDGFR_ protein was detected in 
both invasive and central regions in the GBM tumors and in WHO 
grade II and III tumors (Figure 9, A–F, Supplemental Figures 9 and 
10, and data not shown). Notably, both p-SrcY418 and p-Dock180Y1811 
were also expressed in the majority of PDGFR_-positive tumor cells 
in invasive and central regions of clinical glioma specimens (Figure 
9, B, C, E, and F, Supplemental Figure 10, B, C, E, and F, and Sup-
plemental Table 2). In contrast, minimal expression of PDGFR_, 
p-SrcY418, and p-Dock180Y1811 was found in normal brain and WHO 
grade I glioma specimens (Supplemental Figure 11 and data not 
shown). Spearman’s rank correlation analysis of the expression of 
PDGFR_ and p-Dock180Y1811 in clinical glioma specimens by IHC 
staining corroborated the correlation coefficient between border 
and border areas (r2 = 0.9000; P < 0.05), center and center regions 
(r2 = 0.9000; P < 0.05), and invasion and invasion areas (r2 = 0.8721; 
P < 0.05) (Supplemental Tables 3 and 4).
To further validate these findings, we examined expression of 
PDGFR_, p-SrcY418, and p-Dock180Y1811 by IB analyses in tumor 
lysates from a separate and independent cohort of 38 clinical GBM 
specimens. PDGFR_ was overexpressed in 4 GBMs (tumors 4, 13, 14, 
and 30), and PDGFR_ protein was detected at moderate to high lev-
els in another 11 tumors (Figure 9G). Dock180 was detected at high 
levels in 25 of these 38 tumors, and p-SrcY418 and phosphorylated 
p21-activated kinase 1/2 (p-PAK1/2; activated by binding to p21-
GTPases, including Rac1) were found in all tumors at different lev-
els. Interestingly, p-Dock180Y1811 was coexpressed with p-SrcY418 and 
p-PAK1/2 in 8 PDGFR_-expressing GBMs (Figure 9G), which sug-
gested activation of Src/Dock180/Rac1 signaling in these PDGFR_-
expressing GBMs. Kaplan-Meier analysis showed that patients with 
high levels of both PDGFR_ and p-Dock180Y1811 had significantly 
shorter overall survival compared with those with low PDGFR_ 
and p-Dock180Y1811 (Figure 9, H and I). Finally, we searched for 
p-Dock180Y1811 in proteomic studies of p-Y proteins in human can-
cers and found that p-Dock180Y1811 has previously been detected in 
clinical specimens and cell lines of various types of human cancers, 
including gliomas, lung, breast, bladder, ovarian, oropharyngeal, 
and nonmelanoma skin cancers (http://www.phosphosite.org and 
ref. 25). Taken together, these data suggest that Dock180 is found 
phosphorylated at its Y1811 site, and p-Dock180Y1811 is coexpressed 
with PDGFR_ and p-SrcY418 in clinical human glioma specimens 
and could be a clinically useful marker in the diagnosis and assess-
ment of outcome in GBMs with PDGFR_ overexpression.
%JTDVTTJPO
Here we report a mechanism by which Rac1, a key modulator of cell 
motility and growth, is activated by its GEF, Dock180, in PDGFR_-
promoted glioma tumorigenesis (Figure 10). We found that Dock180 
was not only required for PDGFR_-promoted glioma cell growth, 
survival, and invasion in vitro and in vivo, but was also specifically 
p-Y at Y1811 in an Src-dependent manner. p-Dock180Y1811 medi-
ated PDGFR_ stimulation of glioma tumorigenesis through asso-
ciation of Dock180 with CrkII and p130Cas and activation of Rac1. 
Additionally, Dock180 was associated with the PDGFR_ receptor 
itself upon PDGF-A stimulation, and, without affecting induced 
p-Dock180Y1811, disruption of Dock180 association with PDGFR_ 
impeded PDGFR_-promoted glioma cell migration. Furthermore, 
p-Dock180Y1811 and p-SrcY418 were coexpressed with PDGFR_ in clin-
ical glioma specimens, and p-Dock180Y1811 was detected in several 
types of human cancers, including gliomas. Additionally, expression 
of p-Dock180Y1811 and PDGFR_ correlated with a very poor clinical 
prognosis in patients with gliomas. Taken together, our results sug-
gest a critical role of activation of p-Dock180Y1811/Rac1 signaling in 
promoting cancer tumorigenesis.
Genetic studies have established a pathway of Dock180/CrkII/Rac 
in C. elegans (11) and placed Dock180/Rac1 downstream of PVR (the 
homolog of PDGFR/VEGFR) in Drosophila (14, 26). In the present 
study, we further established that PDGF-A stimulation of PDGFR_ 
induced Src-dependent p-Y at Dock180Y1811, leading to the formation 
of the Dock180/CrkII/p130Cas complex and activation of Rac1 sig-
naling and thereby promoting glioma cell growth, survival, and inva-
sion (Figure 10). Since Rac1 is a direct downstream target of Dock180 
(11) and mediates cancer cell growth, survival, and motility (10, 15, 
27), inhibition of Dock180 by siRNA knockdown or reversion with 
Dock180Y1811F* abrogated PDGFR_-stimulated Rac1 activity and 
tumorigenic behaviors of glioma cells in vitro and in vivo. Moreover, 
inhibition of Dock180 attenuated PDGFR_ activation of p-Erk1/2, 
but with less reduction of p-Akt. We recently demonstrated that in 
glioblastomas deficient in Ink4a/Arf, overexpressed PDGFR_ pro-
motes tumorigenesis through the PI3K/Akt/mTOR-mediated path-
way regulated by SHP-2 (8). Since both PDGFR_/PI3K signaling and 
PDGFR_/Src/Dock180/Rac1 signaling stimulate p-Akt, inhibition of 
Dock180 only partially reduced p-Akt, but attenuated PDGFR_-pro-
moted survival and growth of glioma cells. On the other hand, inhi-
bition of PI3K by LY294002 did not affect PDGF-A–induced p-Y of 
PDGFR_ and p-Y of Dock180, but abrogated PDGF-A stimulation of 
Rac1 activities and cell migration, corroborating a recent study show-
ing that PI3K is upstream of Rac1 in PDGFR_-induced cell migration 
(21). Additionally, the requirement for both PI3K/Akt/SHP-2/mTOR 
and Src/Dock180/Rac1 signaling in PDGFR_-promoted glioma 
tumorigenesis (ref. 8 and the present study) recapitulates the hetero-
geneity of glioblastomas that engenders their malignancy through 
multiple pathways. This hypothesis is further supported by our data 
showing that activated PAK1/2 (p-PAK1/2) and active Src (p-SrcY418) 
were found in each of the 38 clinical GBM specimens analyzed, where-
as active Dock180 (p-Dock180Y1811) was only observed in 10 of them. 
PAK1/2 is activated by several p21-GTPases, including Rac1 and 
Cdc42 (9). We also made a similar observation in our IHC, studies in 
which p-Dock180Y1811 was absent in a number of glioma samples that 
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express PDGFR_ and/or p-SrcY418. Since PDGFR_ and p-SrcY418 are 
activated in glioblastomas (2, 3, 28), GBMs that lack p-Dock180Y1811 
might use alternative signaling pathways for their tumorigenesis. 
Taken together, our results not only corroborated with genetic stud-
ies showing that Dock180/Rac mediates cell migration induced by 
PDGFR (PVR in Drosophila) (14), but also integrate PDGFR_ activa-
tion of Src into p-Dock180Y1811/Rac1–promoted glioma cell growth, 
survival, and invasion (Figure 10).
Dock180 was identified as a binding protein for c-Crk through 
its C-terminal PxxP region (29). The PxxP domain–mediated 
formation of a Dock180/CrkII/p130Cas complex is required for 
integrin stimulation of Rac1 and cell motility (11). Importantly, 
Y1811 is located within this PxxP domain (Figure 3B), which is 
highly conserved in Dock180 from opossum to humans, but not 
in other members of the Dock family (Figure 3F and Supplemen-
tal Figure 2). Since Dock180 activity is regulated by a conforma-
tional change upon ELMO1 association (11), it is possible that the 
PDGFR_-induced p-Dock180Y1811 at its C-terminal PxxP domain 
and formation of the Dock180/CrkII/p130Cas complex caused 
a further conformation change, resulting in increased Dock180 
binding to Rac1 and Rac1 activation. This provides a rationale for 
the observed biological and biochemical consequences of the specific 
p-Dock180Y1811 in PDGFR_-stimulated gliomagenesis. Furthermore, 
overexpression of PDGFR_ in clinical GBMs (4), co-overexpression 
of p-Dock180Y1811 with PDGFR_ and p-SrcY418 in clinical glioma 
specimens, and the occurrence of p-Dock180Y1811 in several types of 
human cancers (ref. 25 and http://www.phosphosite.org) suggest 
that p-Dock180Y1811 could be specifically responsible for the activa-
tion of Rac1 that promotes tumorigenesis of human cancers.
PDGF induces Src association with PDGFR_ at a specific p-Y 
docking site in the receptor (30). Moreover, upon stimulation of 
RTKs, Src induces p-Y of several GEFs, such as Vav2 (10), which 
suggests that Src-dependent p-Y of GEFs could be a mechanism in 
RTK-promoted tumorigenesis. Our data support this hypothesis. 
In contrast to a previous report of p-Y of ELMO1 by Src family 
kinase Hck (31), we did not detect p-Y of ELMO1 upon PDGFR_ 
activation. However, p-Dock180Y1811 was markedly induced in 
PDGF-A–stimulated glioma cells and primary GBM5 cells with 
PDGFR_ overexpression, and inhibition of Src impaired PDGFR_-
induced p-Dock180Y1811. In silico analyses identified Y1811 and 
other potential p-Y sites in Dock180 as Src substrate sites. Our 
data validated Y1811 as a PDGFR_-induced Src p-Y site. Addition-
ally, there was a minor p-Y site of Dock180 that was induced by 
PDGFR_ activation (Figure 3E), but was not affected by Src inhibi-
tors (Figure 6A), suggestive of a Src-independent p-Y of Dock180 
not involved in PDGFR_-stimulated cell migration (Figure 6B). 
Based on these data, it would be predicted that Src family kinase 
inhibitors such as Dasatinib or AZD0530 (20) could be effective to 
inhibit PDGFR_-promoted glioma tumorigenesis in the brains of 
animals. However, caution is in order with this idea, since the Src 
family kinase inhibitors PP2 and SU6656 were previously shown to 
have minimal or moderate impact on PDGFR_-stimulated anchor-
age-independent growth of human glioma cells in vitro (8).
Multiple Rho GEFs interact with RTKs through various functional 
domains, affecting their GEF activities (12). We showed that PDGF-A 
induced an association of Dock180 with PDGFR_ through its N-ter-
minal domain (1–159 aa residues), which was critical for PDGFR_-
stimulated Rac1 activity and glioma cell migration. The interaction 
region of Dock180 contains a SH3 domain that binds to ELMO1. 
Reexpression of shRNA-resistant Dock1806160*, but not Dock180WT*, 
in LN444/PDGF-A/shDock180 cells resulted in loss of interaction 
among Dock1806160*, PDGFR_, and ELMO1, loss of Rac1 activity, 
and decreased glioma cell migration without affecting induction of 
p-Y of Dock180. Additionally, a double Dock1806160-Y1811F* mutant 
showed an additive effect on the inhibition of PDGFR_ stimulation. 
Our data could explain the previous observation that overexpression 
of Dock180 lacking the DHR-1 domain — which is a PtdIns(3,4,5)P3-
binding domain — leads to activation of Rac1 (32) and does not 
require ELMO1 for this activity (11). We speculate that PDGF-A 
induces association of Dock180 with PDGFR_ through the N-termi-
nal region (1–159 aa residues) of Dock180, which probably is adjacent 
to or overlaps with the SH3 domain that binds to ELMO1, thereby 
opening the inhibitory folding configuration of Dock180 in unstim-
ulated cells (11). Interaction of Dock180 with PDGFR_ could addi-
tionally target Dock180 to the membrane in synergy with the DHR-1 
domain, inducing formation of the Dock180/CrkII/p130Cas complex 
and stimulating Rac1 activities and cell motility (11). These data also 
support the hypothesis that DHR-1 plays a role in dynamic membrane 
targeting of the Rho GEF activity of Dock180 in PDGFR_-activated 
cells (33). On the other hand, we found that association of Dock180 to 
PDGFR_ was independent of Src-induced p-Dock180Y1811, since the 
Dock180Y1811F mutant was still able to bind to PDGFR_ upon PDGF-
A stimulation. Moreover, disruption of Dock180 binding to PDGFR_, 
a single Dock180Y1811F mutant, or a double Dock1806160-Y1811F* 
mutant abrogated PDGF-A activation of Rac1 and cell motility. The 
requirement of these 2 separate mechanisms fits well with a hypothet-
ical 2-step model of bipartite GEF activation (11). Namely, in addition 
to association with ELMO1, PDGF-A–induced binding of Dock180 
to PDGFR_ targets Dock180 to the membrane, thereby facilitating 
interaction of ELMO1 and Dock180 with nucleotide-free Rac1. Since 
Y1811 is located farther away from the N-terminal SH3 domain of 
Dock180 and may not involve in the interaction of Dock180 with 
Rac1, it is possible that the PxxP domain with unphosphorylated 
Dock180Y1811 could hinder the loading of GTP into nucleotide-free 
Rac1. Src-induced p-Dock180Y1811 and formation of the Dock180/
CrkII/p130Cas complex caused a further conformation change of 
Dock180, thereby allowing GTP loading to nucleotide-free Rac1 and 
resulting in activation of Rac1 signaling and various cellular func-
tions. However, this hypothesis warrants further investigation.
In summary, our data reveal a mechanism by which PDGFR_ 
stimulates glioma tumorigenesis through PDGFR_-induced Src-
dependent p-Y of Dock180Y1811 as well as Dock180 association 
with activated PDGFR_, thereby activating the Dock180/CrkII/
p130Cas/Rac1 pathway. This is underscored by coexpression of 
p-Dock180Y1811 and p-SrcY418 with overexpressed PDGFR_ in clinical 
glioma specimens and a notable association with very poor patient 
survival. It also fits well with the occurrence of p-Dock180Y1811 that 
is detected by proteomic analysis in various types of human cancers, 
including gliomas. Since p-Y of Rho GEFs is a common mechanism 
affecting GEF activity, and Src is aberrantly activated in human 
cancers, including gliomas, our study suggests that the PDGFR_/
Src/p-Dock180Y1811/Rac1 signaling axis could represent a novel and 
attractive therapeutic target for glioblastomas and other types of 
human cancer that overexpress PDGFR_.
.FUIPET
Cell lines and reagents. HEK293T, glioma U87, U251, U373, and T98G 
cells (all from ATCC); SNB19, LNZ308, LN18, LN235, LN319, LN443, 
and LN444 cells; and unaltered primary human GBM cells were cul-
tured as previously described (15, 24, 34). Rabbit polyclonal antibodies 
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to p-Dock180Y1811 were produced by immunizing animals with a syn-
thetic phosphopeptide corresponding to residues surrounding human 
Dock180Y1811. The antibodies were then affinity purified. YOP PTP was 
from Enzo Life Science; recombinant Src protein was from Active Motif; 
and lentivirus-encoded Src shRNAs were from The Broad Institute. Flag-
Dock180 was provided by M. Matsuda (Kyoto University, Kyoto, Japan); 
PDGFR_68,9 by I. Clarke (University of Toronto, Toronto, Ontario, Cana-
da); PDGF-A and PDGFR_ by C.-H. Heldin (Uppsala University, Uppsala, 
Sweden); CrkII by R. Birge (UMDNJ–New Jersey Medical School, Newark, 
New Jersey, USA); Src-WT, -KD, and -CA by S. Courtneidge (Sanford-
Burnham Medical Research Institute, La Jolla, California, USA); pMXI-
gfp by R. Pieper (UCSF, San Francisco, California, USA); and SNB19 cells 
by Y. Zhou (UCI, Irwin, California, USA).
Purification of recombinant proteins. Protein purifications were performed 
at 4°C. (His)6-tagged Dock180WT and Dock180Y1811F proteins were purified 
from serum-starved HEK293T cells transiently transfected with pcDNA3-
(His)6-Dock180WT and -Dock180Y1811F, respectively. Cells were lysed and 
sonicated. The lysates were centrifuged, and the supernatants were loaded 
onto a Ni+-NTA column in 10 mM imidazole buffer. After washing 2=, 
Ni+-bound proteins were eluted with a 500 mM imidazole buffer followed 
by dialysis against PBS. The purified recombinant Dock180 proteins were 
examined by Coomassie blue staining and IB analyses. The aliquots were 
stored at 80°C until use.
In vitro Src p-Y and Rac1/Dock180 binding assays. 500 ng purified recombinant 
Dock180WT or Dock180Y1811F proteins were incubated with 200 +M cold ATP 
in the presence or absence of 100 ng recombinant active Src kinase (Active 
Motif) in 30 +l reaction buffer (60 mM Hepes-NaOH, pH 7.5, 3 mM MnCl2, 
3 mM MgCl2, 3 M Na3VO4, 1.2 mM DTT, 1.5 +g PEG 20,000) at 30°C for 30 
minutes and then chilled on ice. The reaction products were mixed with an 
equal volume of 2= SDS sample buffer and p-Dock180Y1811, then examined 
by IB analyses using the specific anti–p-Dock180Y1811 antibody.
The effect of Src-induced p-Dock180Y1811 on Rac1 binding was deter-
mined as previously described (22, 23). Briefly, Flag-tagged Dock180WT 
or Dock180Y1811F cDNAs were transfected into HEK293T cells for 48 
hours. Cells were then lysed, and Flag-tagged Dock180WT or Dock-
180Y1811F proteins were subjected to IP using an anti-Flag antibody. The 
precipitates were then treated with 15 +M of a recombinant YOP PTP 
at 30°C for 1 hour in 1= YOP reaction buffer (50 mM citrate, pH 6.0, 
100 mM NaCl, 1 mM EDTA, and 1 mM DTT) containing 1 mg/ml BSA, 
washed 3= with PBS, and incubated with or without a recombinant Src 
kinase at 30°C for 30 minutes. The treated mixtures were washed again 
and incubated with total lysates prepared from HEK293T cells that were 
transfected with a EGFP-Rac1 cDNA with 10 mM EDTA at 4°C for 90 
minutes. The reaction products were mixed with an equal volume of IP 
buffer or 2= SDS sample buffer and examined by IP and IB analyses.
IHC and IB analyses of human and mouse glioma specimens. In total, 134 
primary human glioma specimens were collected from 2001 to 2008 
at Saitama Medical University and Kyorin University. Specimens were 
examined and diagnosed by a neuropathologist, then analyzed by 
IHC using an anti-PDGFR_ antibody (diluted 1:20) as we previously 
described (15). IHC analyses were further performed on 33 specimens 
that were positive for PDGFR_ expression and 9 samples that were 
negative for PDGFR_ expression using specific anti–p-Dock180Y1811 
and anti–p-SrcY418 antibodies (diluted 1:20 and 1:10, respectively). 
Mouse brain sections with various tumors were analyzed by IHC using 
an anti–Ki-67 antibody (diluted 1:200) or a TUNEL staining kit. Imag-
es were captured using a microscope equipped with a digital camera. 
5 random images per section of mouse brains were obtained, and per-
centage of Ki-67– or TUNEL-positive cells was quantified and statisti-
cally analyzed as previously described (8).
A separate and independent cohort of a total of 38 snap-frozen WHO 
grade IV GBM tissue samples were obtained from the University of Pitts-
burgh Medical Center Tissue Bank. These tissue samples were neurologi-
cal specimens discarded as excess tissues and collected and banked by the 
Tissue Bank at the University of Pittsburgh; tumors were examined and 
diagnosed by a neuropathologist. The small frozen fragments of tumor 
tissues (0.07–0.9 g) were processed and analyzed by IB assays (8).
Gene knockdown by siRNA or shRNA; mutagenesis, IP, IB, cell proliferation, and 
viability assays; in vitro cell migration and Rac1 activation assays; mouse glioma 
xenografts; gene expression analysis; and quantitative PCR analysis for gene copy 
numbers. See Supplemental Methods.
Statistics. GraphPad Prism version 4.00 for Windows was used to perform 
1-way ANOVA with Newman-Keuls post-test or paired 2-tailed Student’s 
t test and r2 test as previously described (15). A P value of 0.05 or less was 
considered statistically significant.
Study approval. Studies using human tissues were reviewed and approved 
by the Institutional Review Board involving Human Subjects of the Univer-
sity of Pittsburgh. The specimens were deidentified human tissues; thus, 
no informed consent was required.
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